https://news.medxy.ai/zh/low-dose-colchicine-prevention/Medxy AIzh2026-08-09T09:46:58-07:00低剂量秋水仙碱能否预防急性脑内出血后的血管事件？一项安慰剂对照先导试验的启示 https://news.medxy.ai/ja/colchicine-acute-brain-bleed/Medxy AIja2026-08-09T09:46:43-07:00急性脳内出血後の血管イベント予防における低用量コルヒチンの評価：プラセボ対照パイロット試験からの知見 https://news.medxy.ai/vi/low-dose-colchicine-bleeding/Medxy AIvi2026-08-09T09:46:25-07:00Colchicine liều thấp sau xuất huyết nội não cấp: tín hiệu khả thi từ một thử nghiệm thí điểm có đối chứng giả dược https://news.medxy.ai/evaluating-low-dose-colchicine-for-preventing-vascular-events-after-acute-intracerebral-hemorrhage-insights-from-a-placebo-controlled-pilot-trial/Medxy AIen2026-08-09T09:45:14-07:00Evaluating Low-Dose Colchicine for Preventing Vascular Events After Acute Intracerebral Hemorrhage: Insights from a Placebo-Controlled Pilot Trial https://news.medxy.ai/zh/diverse-readmission-profiles-after-chronic-subdural-hematoma/Medxy AIzh2026-08-09T09:35:47-07:00基于机器学习的慢性硬膜下血肿住院患者再入院特征分析 https://news.medxy.ai/ja/readmission-profiles-after-chronic-subdural-hematoma/Medxy AIja2026-08-09T09:35:30-07:00慢性硬膜下血腫による入院後の再入院に関する機械学習を用いた特性解析 https://news.medxy.ai/vi/recurrent-chronic-subdural-hematoma/Medxy AIvi2026-08-09T09:34:55-07:00Tái nhập viện sau tụ máu dưới màng cứng mạn tính: Góc nhìn từ phân kiểu hình bằng học máy https://news.medxy.ai/diverse-readmission-profiles-after-chronic-subdural-hematoma-insights-from-machine-learning-phenotyping/Medxy AIen2026-08-09T09:33:05-07:00Diverse Readmission Profiles After Chronic Subdural Hematoma: Insights from Machine Learning Phenotyping https://news.medxy.ai/zh/tavapadon-parkinsons-benefits/Medxy AIzh2026-08-09T09:31:06-07:00早期帕金森病中的 tavapadon：3 期试验显示运动获益与安全性前景 https://news.medxy.ai/ja/tavapadon-in-early-parkinsons-disease-promising-phase-3-trial/Medxy AIja2026-08-09T09:30:45-07:00パーキンソン病に対する用量調節可能なタバパドンの安全性、忍容性、および有効性（TEMPO-2）：第3相無作為化プラセボ対照二重盲検試験 https://news.medxy.ai/vi/tavapadon-parkinson/Medxy AIvi2026-08-09T09:30:22-07:00Tavapadon trong bệnh Parkinson giai đoạn sớm: thử nghiệm giai đoạn 3 cho thấy tín hiệu tích cực về an toàn và cải thiện triệu chứng vận động https://news.medxy.ai/tavapadon-in-early-parkinsons-disease-promising-phase-3-trial-highlights-safety-and-motor-symptom-benefits/Medxy AIen2026-08-09T09:28:31-07:00Tavapadon in Early Parkinson’s Disease: Promising Phase 3 Trial Highlights Safety and Motor Symptom Benefits https://news.medxy.ai/zh/men2-children-thyroid-surgery/Medxy AIzh2026-08-09T09:27:33-07:00权衡获益与风险：儿童 MEN2 患者预防性甲状腺切除术结局 https://news.medxy.ai/ja/risk-benefit-balance-2/Medxy AIja2026-08-09T09:27:13-07:00利益とリスクの均衡を探る：小児MEN2患者における予防的甲状腺摘出術の転帰 https://news.medxy.ai/vi/preventive-thyroidectomy-men2/Medxy AIvi2026-08-09T09:26:49-07:00Cắt tuyến giáp dự phòng ở trẻ mắc MEN2: lợi ích ung thư học và nguy cơ phẫu thuật cần được cân bằng https://news.medxy.ai/balancing-benefits-and-risks-prophylactic-thyroidectomy-outcomes-in-pediatric-men2-patients/Medxy AIen2026-08-09T09:25:08-07:00Balancing Benefits and Risks: Prophylactic Thyroidectomy Outcomes in Pediatric MEN2 Patients https://news.medxy.ai/zh/endometriosis-diabetes-risk-2/Medxy AIzh2026-08-08T23:40:40-07:00子宫内膜异位症不同亚型与2型糖尿病风险升高：ARCHES研究带来的启示 https://news.medxy.ai/ja/endometriosis-diabetes-risk/Medxy AIja2026-08-08T23:40:23-07:00子宮内膜症の病型別にみる2型糖尿病リスク上昇：ARCHES研究からの示唆 https://news.medxy.ai/vi/endometriosis-subtypes-diabetes-risk/Medxy AIvi2026-08-08T23:40:02-07:00Các phân nhóm lạc nội mạc tử cung và nguy cơ đái tháo đường type 2: phát hiện nổi bật từ nghiên cứu ARCHES https://news.medxy.ai/linking-endometriosis-subtypes-to-increased-risk-of-type-2-diabetes-insights-from-the-arches-study/Medxy AIen2026-08-08T23:37:43-07:00Linking Endometriosis Subtypes to Increased Risk of Type 2 Diabetes: Insights from the ARCHES Study https://news.medxy.ai/ersodetug-for-refractory-hypoglycemia-due-to-malignant-insulin-secreting-tumors-a-compassionate-use-case-series/Medxy AIen2026-08-08T23:33:45-07:00Ersodetug for Refractory Hypoglycemia Due to Malignant Insulin-Secreting Tumors: A Compassionate Use Case Series https://news.medxy.ai/zh/early-identify-followup/Medxy AIzh2026-08-08T21:30:25-07:00早识别、早随访：显著改善1型糖尿病高风险儿童的临床结局 https://news.medxy.ai/vi/early-detection-diabetes/Medxy AIvi2026-08-08T21:29:51-07:00Phát hiện sớm và theo dõi trẻ có nguy cơ giúp cải thiện rõ rệt kết cục ở đái tháo đường típ 1 https://news.medxy.ai/early-identification-and-monitoring-of-at-risk-children-significantly-improves-outcomes-in-type-1-diabetes/Medxy AIen2026-08-08T21:28:20-07:00Early Identification and Monitoring of At-Risk Children Significantly Improves Outcomes in Type 1 Diabetes https://news.medxy.ai/zh/aldosterone-antagonists-heart-failure/Medxy AIzh2026-08-08T20:20:56-07:00心力衰竭中醛固酮受体拮抗剂在不同种族患者中的疗效与安全性：来自大规模个体参与者数据荟萃分析的启示 https://news.medxy.ai/efficacy-and-safety-of-mineralocorticoid-receptor-antagonists-across-racial-groups-in-heart-failure-insights-from-a-large-scale-individual-participant-data-meta-analysis/Medxy AIen2026-08-08T20:18:37-07:00Efficacy and Safety of Mineralocorticoid Receptor Antagonists Across Racial Groups in Heart Failure: Insights From a Large-Scale Individual Participant Data Meta-Analysis https://news.medxy.ai/zh/math-biomarkers-prostate-cancer/Medxy AIzh2026-08-08T19:19:53-07:00数学生物标志物助力前列腺癌自适应治疗走向个体化 https://news.medxy.ai/ja/psa-personalized-treatment/Medxy AIja2026-08-08T19:19:39-07:00PSA動態で個別化治療を導く──前立腺癌における予測数理バイオマーカーの可能性 https://news.medxy.ai/predictive-mathematical-biomarkers-transform-personalized-adaptive-therapy-in-prostate-cancer/Medxy AIen2026-08-08T19:18:31-07:00Predictive Mathematical Biomarkers Transform Personalized Adaptive Therapy in Prostate Cancer https://news.medxy.ai/zh/standardizing-rct-evidence/Medxy AIzh2026-08-07T21:30:44-07:00厘清基于登记数据库的随机对照试验：以标准化与分类学推动临床证据进阶 https://news.medxy.ai/ja/registry-randomized-trial/Medxy AIja2026-08-07T21:30:19-07:00レジストリベースランダム化比較試験を読み解く：標準化と分類体系による臨床エビデンスの前進 https://news.medxy.ai/vi/randomized-trials/Medxy AIvi2026-08-07T21:30:00-07:00Giải mã các thử nghiệm đối chứng ngẫu nhiên dựa trên sổ đăng ký: Thúc đẩy bằng chứng lâm sàng thông qua chuẩn hóa và hệ thống phân loại https://news.medxy.ai/decoding-registry-based-randomised-controlled-trials-advancing-clinical-evidence-through-standardisation-and-taxonomy/Medxy AIen2026-08-07T21:28:44-07:00Decoding Registry-Based Randomised Controlled Trials: Advancing Clinical Evidence Through Standardisation and Taxonomy https://news.medxy.ai/zh/type-2-diabetes-treatment/Medxy AIzh2026-08-07T21:15:12-07:00TriMaster试验：2型糖尿病精准治疗策略谁更优？临床特征模型胜出 https://news.medxy.ai/ja/trimaster-diabetes-treatment/Medxy AIja2026-08-07T21:14:49-07:00TriMaster試験で検証：2型糖尿病治療における精密アプローチの比較 https://news.medxy.ai/optimizing-type-2-diabetes-treatment-comparing-precision-approaches-in-the-trimaster-trial/Medxy AIen2026-08-07T21:13:04-07:00Optimizing Type 2 Diabetes Treatment: Comparing Precision Approaches in the TriMaster Trial https://news.medxy.ai/zh/cardiac-resynchronization-therapy-in-nonischemic-cardiomyopathy/Medxy AIzh2026-08-07T12:38:38-07:00非缺血性心肌病中CRT是否需要联合除颤器？——基于DECIDE-CRT及相关研究的证据综述与临床启示 https://news.medxy.ai/ja/cardiac-resynchronization-therapy-with-or-without-defibrillator-in-nonischemic-cardiomyopathy/Medxy AIja2026-08-07T12:38:15-07:00非虚血性心筋症におけるCRTは除細動器併用が必要か：DECIDE-CRTと関連研究から読み解くエビデンスと臨床的含意 https://news.medxy.ai/vi/cardiac-resynchronization-therapy-with-or-without-defibrillator/Medxy AIvi2026-08-07T12:37:45-07:00Liệu pháp tái đồng bộ tim có hoặc không kèm máy khử rung ở bệnh cơ tim không do thiếu máu cục bộ: Tổng hợp bằng chứng và hàm ý lâm sàng từ DECIDE-CRT và các nghiên cứu liên quan https://news.medxy.ai/cardiac-resynchronization-therapy-with-or-without-defibrillator-in-nonischemic-cardiomyopathy-2/Medxy AIen2026-08-07T12:36:09-07:00Cardiac Resynchronization Therapy With or Without Defibrillator in Nonischemic Cardiomyopathy: Evidence Synthesis and Clinical Implications from DECIDE-CRT and Related Studies https://news.medxy.ai/zh/u-shaped-between-left-ventricular-and-mortality-in-heart-failure/Medxy AIzh2026-08-07T12:32:53-07:00左心室大小与心力衰竭死亡风险：U型关系的临床启示 https://news.medxy.ai/ja/u-shaped-between-left-ventricular-size-and-mortality-in-heart-failure/Medxy AIja2026-08-07T12:32:35-07:00心不全における左室サイズと死亡率のU字型関係を読み解く https://news.medxy.ai/vi/u-shaped-relationship-between-left-ventricular-size-and-mortality-in-heart-failure/Medxy AIvi2026-08-07T12:32:16-07:00Giải mã mối liên quan hình chữ U giữa kích thước thất trái và tử vong ở bệnh nhân suy tim https://news.medxy.ai/decoding-the-u-shaped-relationship-between-left-ventricular-size-and-mortality-in-heart-failure-patients/Medxy AIen2026-08-07T12:31:15-07:00Decoding the U-Shaped Relationship Between Left Ventricular Size and Mortality in Heart Failure Patients https://news.medxy.ai/zh/combined-transcatheter-mitral-and-tricuspid-edge-to-edge-repair-in-patients-with-moderate-mitral-regurgitation-and-severe-tricuspid-regurgitation/Medxy AIzh2026-08-07T12:07:55-07:00联合经导管二尖瓣与三尖瓣缘对缘修复在中度二尖瓣反流合并重度三尖瓣反流患者中的临床影响 https://news.medxy.ai/transcatheter-mitral-and-tricuspid-edge-to-edge-repair-in-patients-with-moderate-mitral-regurgitation/Medxy AIen2026-08-07T12:06:02-07:00Impact of Combined Transcatheter Mitral and Tricuspid Edge-to-Edge Repair in Patients with Moderate Mitral Regurgitation and Severe Tricuspid Regurgitation https://news.medxy.ai/zh/7-year-outcomes-after-tavr-versus-savr-in-low-risk-aortic-stenosis-patients/Medxy AIzh2026-08-07T12:04:58-07:00TAVR 与 SAVR 在低风险主动脉瓣狭窄患者中的 7 年健康结局：PARTNER 3 试验解读 https://news.medxy.ai/ja/7-year-health-outcomes-after-tavr-versus-savr-in-low-risk-aortic-stenosis-patients/Medxy AIja2026-08-07T12:04:38-07:00低リスク大動脈弁狭窄症におけるTAVRとSAVRの7年転帰：PARTNER 3試験から得られた知見 https://news.medxy.ai/vi/seven-year-health-outcomes-after-tavr-versus-savr-in-low-risk-aortic-stenosis-patients/Medxy AIvi2026-08-07T12:04:18-07:00Sau 7 năm, TAVR và SAVR mang lại kết cục sức khỏe ra sao ở bệnh nhân hẹp động mạch chủ nguy cơ thấp? Dữ liệu từ thử nghiệm PARTNER 3 https://news.medxy.ai/seven-year-health-outcomes-after-tavr-versus-savr-in-low-risk-aortic-stenosis-patients-insights-from-the-partner-3-trial/Medxy AIen2026-08-07T12:03:14-07:00Seven-Year Health Outcomes After TAVR Versus SAVR in Low-Risk Aortic Stenosis Patients: Insights from the PARTNER 3 Trial https://news.medxy.ai/zh/lv-hypertrabeculation-in-dilated-cardiomyopathy/Medxy AIzh2026-08-07T12:01:02-07:00扩张型心肌病中的左心室过度肌小梁化：预后提示与临床意义 https://news.medxy.ai/ja/left-ventricular-hypertrabeculation-in-dilated-cardiomyopathy/Medxy AIja2026-08-07T12:00:44-07:00拡張型心筋症における左室過剰肉柱形成：予後の見通しと臨床的意義 https://news.medxy.ai/vi/left-ventricular-hypertrabeculation-in-dilated-cardiomyopathy-prognostic/Medxy AIvi2026-08-07T12:00:24-07:00Tăng bè thất trái trong bệnh cơ tim giãn: ý nghĩa tiên lượng và hàm ý lâm sàng https://news.medxy.ai/left-ventricular-hypertrabeculation-in-dilated-cardiomyopathy-prognostic-insights-and-clinical-implications/Medxy AIen2026-08-07T11:59:04-07:00Left Ventricular Hypertrabeculation in Dilated Cardiomyopathy: Prognostic Insights and Clinical Implications https://news.medxy.ai/zh/electronic-patient-reported-outcome-with-alert-based-interventions-in-metastatic-breast-cancer-2/Medxy AIzh2026-08-07T11:55:09-07:00转移性乳腺癌的电子患者报告结局监测：警报触发干预的证据与临床启示 https://news.medxy.ai/ja/electronic-patient-reported-outcome-with-alert-based-interventions-in-metastatic-breast-cancer/Medxy AIja2026-08-07T11:54:46-07:00転移性乳がんにおける電子患者報告アウトカムモニタリングとアラート介入：エビデンスと臨床的意義の整理 https://news.medxy.ai/vi/electronic-patient-reported-outcome-monitoring-with-alert-based-interventions-in-metastatic-breast-cancer/Medxy AIvi2026-08-07T11:54:21-07:00Theo dõi kết cục do người bệnh tự báo cáo bằng điện tử trong ung thư vú di căn: bằng chứng và ý nghĩa lâm sàng của can thiệp dựa trên cảnh báo https://news.medxy.ai/electronic-patient-reported-outcome-monitoring-with-alert-based-interventions-in-metastatic-breast-cancer-a-review-of-evidence-and-clinical-implications/Medxy AIen2026-08-07T11:53:17-07:00Electronic Patient-Reported Outcome Monitoring With Alert-Based Interventions in Metastatic Breast Cancer: A Review of Evidence and Clinical Implications https://news.medxy.ai/zh/enfortumab-vedotin-induced-cutaneous-toxicity-and-survival-in-urothelial-carcinoma/Medxy AIzh2026-08-07T11:49:11-07:00恩福妥珠单抗维多汀相关皮肤毒性：晚期尿路上皮癌生存获益的潜在标志 https://news.medxy.ai/ja/enfortumab-vedotin-induced-cutaneous-toxicity-a-marker-of-survival-in-urothelial-carcinoma/Medxy AIja2026-08-07T11:48:48-07:00エンホルツマブ ベドチンによる皮膚毒性は予後改善のサインか：進行尿路上皮癌における生存との関連 https://news.medxy.ai/vi/enfortumab-vedotin-induced-cutaneous-toxicity-a-marker-of-survival-in-advanced-urothelial-carcinoma/Medxy AIvi2026-08-07T11:48:07-07:00Độc tính da do Enfortumab Vedotin: Dấu ấn gợi ý cải thiện sống còn trong ung thư biểu mô niệu mô tiến triển https://news.medxy.ai/enfortumab-vedotin-induced-cutaneous-toxicity-a-marker-of-improved-survival-in-advanced-urothelial-carcinoma/Medxy AIen2026-08-07T11:47:03-07:00Enfortumab Vedotin-Induced Cutaneous Toxicity: A Marker of Improved Survival in Advanced Urothelial Carcinoma https://news.medxy.ai/zh/antifungal-therapies-for-tinea-capitis/Medxy AIzh2026-08-07T11:46:23-07:00头癣抗真菌治疗效果如何？中国多中心研究给出新线索 https://news.medxy.ai/ja/efficacy-of-antifungal-therapies-for-tinea-capitis/Medxy AIja2026-08-07T11:46:05-07:00頭部白癬に対する抗真菌治療の有効性：中国の多施設研究から見えたこと https://news.medxy.ai/vi/efficacy-of-antifungal-therapies-in-tinea-capitis/Medxy AIvi2026-08-07T11:45:45-07:00Điều trị nấm da đầu: hiệu quả của các thuốc kháng nấm qua nghiên cứu đa trung tâm tại Trung Quốc https://news.medxy.ai/efficacy-of-antifungal-therapies-in-tinea-capitis-insights-from-a-multicenter-study-in-china/Medxy AIen2026-08-07T11:44:32-07:00Efficacy of Antifungal Therapies in Tinea Capitis: Insights from a Multicenter Study in China https://news.medxy.ai/zh/migraine-and-sinus-headaches-in-patients-with-primary-rhinoplasty/Medxy AIzh2026-08-07T11:42:13-07:00初次鼻整形患者中偏头痛与鼻窦性头痛的发生率：临床综述 https://news.medxy.ai/ja/migraine-and-sinus-headaches-in-patients-undergoing-primary-rhinoplasty/Medxy AIja2026-08-07T11:41:52-07:00一次鼻形成術における片頭痛・副鼻腔頭痛の頻度：臨床レビュー https://news.medxy.ai/vi/frequency-of-migraine-and-sinus-headaches-in-patients-undergoing-primary-rhinoplasty/Medxy AIvi2026-08-07T11:41:28-07:00Đau nửa đầu và đau đầu do xoang ở bệnh nhân phẫu thuật tạo hình mũi nguyên phát: tổng quan lâm sàng https://news.medxy.ai/frequency-of-migraine-and-sinus-headaches-in-patients-undergoing-primary-rhinoplasty-a-clinical-review/Medxy AIen2026-08-07T11:40:24-07:00Frequency of Migraine and Sinus Headaches in Patients Undergoing Primary Rhinoplasty: A Clinical Review https://news.medxy.ai/zh/%e6%8f%90%e5%8d%87%e4%b9%b3%e6%88%bf%e7%9a%ae%e7%93%a3%e5%ad%98%e6%b4%bb%e8%af%84%e4%bc%b0%ef%bc%9a%e6%bf%80%e5%85%89%e6%95%a3%e6%96%91%e5%af%b9%e6%af%94%e6%88%90%e5%83%8f%e4%b8%8e%e5%90%b2%e5%93%9a/Medxy AIzh2026-08-07T11:38:52-07:00提升乳房皮瓣存活评估：激光散斑对比成像与吲哚菁绿荧光谁更优 https://news.medxy.ai/ja/%e4%b9%b3%e6%88%bf%e3%83%95%e3%83%a9%e3%83%83%e3%83%97%e7%94%9f%e5%ad%98%e6%80%a7%e8%a9%95%e4%be%a1%e3%81%ae%e6%96%b0%e5%b1%95%e9%96%8b%ef%bc%9a%e3%83%ac%e3%83%bc%e3%82%b6%e3%83%bc%e3%83%bb%e3%82%b9/Medxy AIja2026-08-07T11:38:21-07:00乳房フラップ生存性評価の新展開：レーザー・スペックル・コントラスト・イメージングとインドシアニングリーン蛍光法の比較 https://news.medxy.ai/vi/nang-cao-danh-gia-kha-nang-song-cua-vat-vu-laser-speckle-contrast-imaging-so-voi-huynh-quang-indocyanine-green/Medxy AIvi2026-08-07T11:38:01-07:00Nâng cao đánh giá khả năng sống của vạt vú: Laser Speckle Contrast Imaging so với huỳnh quang Indocyanine Green https://news.medxy.ai/advancing-breast-flap-viability-assessment-laser-speckle-contrast-imaging-versus-indocyanine-green-fluorescence/Medxy AIen2026-08-07T11:37:15-07:00Advancing Breast Flap Viability Assessment: Laser Speckle Contrast Imaging Versus Indocyanine Green Fluorescence https://news.medxy.ai/zh/higher-education-students-in-england-who-died-by-suspected-suicide-a-national-retrospective-case-series-study/Medxy AIzh2026-08-07T11:35:04-07:00英格兰高等教育学生疑似自杀死亡特征：一项全国性回顾性病例系列研究 https://news.medxy.ai/vi/characteristics-of-higher-education-students-in-england-who-died-by-suspected-suicide/Medxy AIvi2026-08-07T11:34:15-07:00Đặc điểm của sinh viên giáo dục đại học ở Anh tử vong do nghi ngờ tự sát: nghiên cứu chuỗi ca hồi cứu toàn quốc https://news.medxy.ai/characteristics-of-higher-education-students-in-england-who-died-by-suspected-suicide-a-national-retrospective-case-series-study/Medxy AIen2026-08-07T11:32:39-07:00Characteristics of Higher-Education Students in England Who Died by Suspected Suicide: A National Retrospective Case Series Study https://news.medxy.ai/zh/h3-1-nucleosomes-for-renal-replacement-therapy-and-mortality-in-sepsis/Medxy AIzh2026-08-07T11:24:41-07:00H3.1 核小体作为脓毒症肾脏替代治疗与死亡风险预测生物标志物：来自 SISPCT 试验的分析 https://news.medxy.ai/ja/h3-1-nucleosomes-as-biomarkers-for-renal-replacement-therapy-and-mortality-in-sepsis/Medxy AIja2026-08-07T11:24:06-07:00敗血症の予後予測を担うH3.1ヌクレオソーム：腎代替療法と死亡率を見据えたSISPCT試験解析 https://news.medxy.ai/vi/h3-1-nucleosomes-as-biomarkers-for-renal-replacement-therapy-and-mortality-in-sepsis-insights-from-the-sispct-trial/Medxy AIvi2026-08-07T11:23:28-07:00Nucleosome H3.1 như dấu ấn sinh học tiên lượng trong điều trị thay thế thận và tử vong ở nhiễm khuẩn huyết: phân tích từ thử nghiệm SISPCT https://news.medxy.ai/h3-1-nucleosomes-as-predictive-biomarkers-for-renal-replacement-therapy-and-mortality-in-sepsis-insights-from-the-sispct-trial/Medxy AIen2026-08-07T11:21:32-07:00H3.1 Nucleosomes as Predictive Biomarkers for Renal Replacement Therapy and Mortality in Sepsis: Insights from the SISPCT Trial https://news.medxy.ai/zh/enhance-trust-empathy-and-comfort-in-serious-illness-communication-4/Medxy AIzh2026-08-07T11:06:57-07:00医生的情绪表达与自我披露：如何在严重疾病沟通中增强信任、同理心与舒适感 https://news.medxy.ai/ja/enhance-trust-empathy-and-comfort-in-serious-illness-communication-3/Medxy AIja2026-08-07T11:06:31-07:00重篤な疾患の対話をより良くするには：医師の感情表出と自己開示が信頼・思いやりに与える好影響 https://news.medxy.ai/vi/enhance-trust-empathy-and-comfort-in-serious-illness-communication-2/Medxy AIvi2026-08-07T11:06:12-07:00Cảm xúc và sự chân thành của bác sĩ trong trao đổi về bệnh nặng: củng cố niềm tin và lòng trắc ẩn https://news.medxy.ai/zh/effectiveness-of-2024-2025-covid19-vaccines-in-adults/Medxy AIzh2026-08-07T11:04:02-07:002024—2025年成人 COVID-19 疫苗有效性估计：近期证据的综合综述 https://news.medxy.ai/ja/effectiveness-of-2024-2025-covid-19-vaccines-in-adults/Medxy AIja2026-08-07T11:03:31-07:00成人における2024～2025年COVID-19ワクチンの有効性推定：最新エビデンスの包括的レビュー https://news.medxy.ai/vi/estimated-effectiveness-of-2024-2025-covid-19-vaccines-in-adults/Medxy AIvi2026-08-07T11:03:08-07:00Hiệu quả của vắc xin COVID-19 2024–2025 ở người lớn: Tổng quan toàn diện về bằng chứng gần đây https://news.medxy.ai/estimated-effectiveness-of-2024-2025-covid-19-vaccines-in-adults-a-comprehensive-review-of-recent-evidence/Medxy AIen2026-08-07T11:00:13-07:00Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults: A Comprehensive Review of Recent Evidence https://news.medxy.ai/ja/acp-2026-position-paper-a-policy-roadmap-to-obesity/Medxy AIja2026-08-07T10:56:17-07:00ACP 2026年声明：肥満予防・治療を「手が届く・受けやすい・スティグマのない」ものにするための政策ロードマップ https://news.medxy.ai/vi/acp-2026-position-paper-a-policy-roadmap-to-obesity-prevention-and-treatment/Medxy AIvi2026-08-07T10:55:37-07:00ACP 2026: Lộ trình chính sách giúp phòng ngừa và điều trị béo phì trở nên dễ tiếp cận, hợp túi tiền và không kỳ thị https://news.medxy.ai/zh/acp-2026-position-paper-a-policy-roadmap-to-make-obesity-prevention-and-treatment/Medxy AIzh2026-08-07T10:54:57-07:00ACP 2026立场文件：让肥胖预防与治疗更可负担、可及并消除污名的政策路线图 https://news.medxy.ai/acp-2026-position-paper-a-policy-roadmap-to-make-obesity-prevention-and-treatment-affordable-accessible-and-stigma-free/Medxy AIen2026-08-07T10:51:17-07:00ACP 2026 Position Paper: A Policy Roadmap to Make Obesity Prevention and Treatment Affordable, Accessible, and Stigma-Free https://news.medxy.ai/zh/advancing-diagnosis-in-myeloproliferative-neoplasms-non-invasive-multiparametric-profiling/Medxy AIzh2026-08-07T10:49:12-07:00破解骨髓增殖性肿瘤诊断难题：ET、前纤维化期与显性骨髓纤维化的非侵入性多参数分型 https://news.medxy.ai/ja/noninvasive-multiparametric-for-et-premyelo%ef%ac%81brosis-and-overt-myelo%ef%ac%81brosis/Medxy AIja2026-08-07T10:48:54-07:00骨髄増殖性腫瘍の診断を前進させる：ET、前線維化期骨髄線維症、顕性骨髄線維症を非侵襲的多項目プロファイリングで読み解く https://news.medxy.ai/vi/non-invasive-multiparametric-for-et-premyelo%ef%ac%81brosis-and-overt-myelo%ef%ac%81brosis/Medxy AIvi2026-08-07T10:48:25-07:00Cải thiện chẩn đoán trong các u tăng sinh tủy: hồ sơ đa thông số không xâm lấn của ET, preMF và PMF xơ hóa rõ https://news.medxy.ai/advancing-diagnosis-in-myeloproliferative-neoplasms-non-invasive-multiparametric-profiling-of-et-premyelo%ef%ac%81brosis-and-overt-myelo%ef%ac%81brosis/Medxy AIen2026-08-07T10:47:13-07:00Advancing Diagnosis in Myeloproliferative Neoplasms: Non-invasive Multiparametric Profiling of ET, Premyelofibrosis, and Overt Myelofibrosis https://news.medxy.ai/zh/swisslegio-score-legionella-in-community-acquired-pneumonia/Medxy AIzh2026-08-07T10:18:26-07:00SwissLEGIO 评分：简化社区获得性肺炎中军团菌检测的实用工具 https://news.medxy.ai/ja/swisslegio-score-legionella-testing-in-community-acquired-pneumonia/Medxy AIja2026-08-07T10:17:53-07:00SwissLEGIOスコア：地域性肺炎におけるレジオネラ検査を効率化する簡便な指標 https://news.medxy.ai/vi/swisslegio-score-streamline-legionella-testing-in-community-acquired-pneumonia/Medxy AIvi2026-08-07T10:17:30-07:00SwissLEGIO: Thang điểm đơn giản hóa giúp tối ưu xét nghiệm Legionella trong viêm phổi mắc phải cộng đồng https://news.medxy.ai/swisslegio-score-a-simplified-tool-to-streamline-legionella-testing-in-community-acquired-pneumonia/Medxy AIen2026-08-07T10:16:23-07:00SwissLEGIO Score: A Simplified Tool to Streamline Legionella Testing in Community-Acquired Pneumonia